Q-omics provides the consensus-scored KLHL28 profile across patient tissues and cancer cell-line models. KLHL28 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLHL28 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KLHL28 RNA expression shows 21,432 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where KLHL28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL28 survival associations across molecular data types. KLHL28 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL28 RNA expression–survival associations across cancer types. High KLHL28 expression shows unfavorable associations in ACC, UVM and KICH, but favorable associations in KIRC, LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLHL28 RNA expression.
This table summarizes KLHL28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL28 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, CHOL and ESCA. The HNSC box plot shows higher KLHL28 RNA expression in tumor versus normal tissue (log2 FC = +0.405, t-test p = .001).
This table shows molecular features associated with KLHL28 in patient tissues and cancer cell lines. In patient samples, KLHL28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
